Screener
Intellia Therapeutics NTLA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from options exercised | 16 | - |
| Issuance of shares through employee stock purchase plan | 1,520 | 1,237 |
| Net cash provided by financing activities | 229,685 | 14,652 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (46,036) | (32,662) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 167,568 | 202,787 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $121,532 | $170,125 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents to condensed consolidated balance sheet: | ||
| Cash and cash equivalents | $106,128 | $156,172 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's net change in cash?
- Intellia Therapeutics (NTLA) reported net change in cash of -$28.57M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Intellia Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude